Added to YB: 2025-06-10
Pitch date: 2025-06-08
1681.HK [neutral]
Consun Pharmaceutical Group Limited
+42.39%
current return
Author Info
Momentum Financial researches stocks from around the world to invest in for the long-term. Sign up for the newsletter.
Company Info
Consun Pharmaceutical Group Limited, together with its subsidiaries, produces and sells pharmaceutical products in Mainland China.
Market Cap
HKD 10.8B
Pitch Price
HKD 10.54
Price Target
N/A
Dividend
5.29%
EV/EBITDA
5.36
P/E
9.34
EV/Sales
2.02
Sector
Pharmaceuticals
Category
growth
Consun Pharma News - June 2025.
1681.HK (update): Consun Pharma's kidney disease focus aligns with WHO resolution. Key catalysts: Gadopentate (40% market share) entering centralized purchasing; State-protected Yishen Huashi (110M yuan, +27.2% YoY); SK-09 clinical trial approval for podocyte diseases; imaging contrast products with 60%+ margins despite price cuts.
Read full article (11 min)